Identification and Characterization of Homing Peptides Using In Vivo Peptide Phage Display.

Each normal organ and pathological condition expresses a distinct set of molecules on their vasculature. These molecular signatures have been efficiently profiled using in vivo phage display. Several peptides homing to tumor blood vessels, lymphatic vessels, and/or tumor cells as well as to various normal organs have been isolated using this method. The in vivo screening of phage libraries has also revealed novel tissue-specific biomarkers of the normal and diseased vasculature. Tumor-homing peptides have been successfully used to target therapeutics and imaging agents to tumors. In vivo phage display has also been used in the identification of cell and/or tumor type-specific cell-penetrating peptides, which further facilitate the transmembrane delivery of various cargo molecules into cells. In this review we describe experimental setup for a combined ex vivo and in vivo screening procedure to select both conventional and cell-penetrating peptides homing to brain tumors.

[1]  E. Ruoslahti,et al.  Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma , 2011, Proceedings of the National Academy of Sciences.

[2]  H. Hoogenboom.  Overview of antibody phage-display technology and its applications. , 2002, Methods in molecular biology.

[3]  Hélder A Santos,et al.  Tumour homing peptide-functionalized porous silicon nanovectors for cancer therapy. , 2013, Biomaterials.

[4]  Erkki Ruoslahti,et al.  A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[5]  P. Laakkonen,et al.  Peptide-based glioma-targeted drug delivery vector gHoPe2. , 2013, Bioconjugate chemistry.

[6]  Erkki Ruoslahti,et al.  Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. , 2003, Cancer cell.

[7]  Simon C Watkins,et al.  Identification of a Cardiac Specific Protein Transduction Domain by In Vivo Biopanning Using a M13 Phage Peptide Display Library in Mice , 2010, PloS one.

[8]  Heikki Joensuu,et al.  Novel Target for Peptide-Based Imaging and Treatment of Brain Tumors , 2014, Molecular Cancer Therapeutics.

[9]  Erkki Ruoslahti,et al.  αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.

[10]  Ü. Langel,et al.  A Novel Cell-penetrating Peptide, M918, for Efficient Delivery of Proteins and Peptide Nucleic Acids. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  Erkki Ruoslahti,et al.  A tumor-homing peptide with a targeting specificity related to lymphatic vessels , 2002, Nature Medicine.

[12]  P. Robbins,et al.  Identification and characterization of tissue-specific protein transduction domains using peptide phage display. , 2011, Methods in molecular biology.

[13]  Ü. Langel,et al.  Assessing the delivery efficacy and internalization route of cell-penetrating peptides , 2007, Nature Protocols.

[14]  Erkki Ruoslahti,et al.  Targeting the prostate for destruction through a vascular address , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R Pasqualini,et al.  NG2 proteoglycan-binding peptides target tumor neovasculature. , 1999, Cancer research.

[16]  Erkki Ruoslahti,et al.  A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  E. Ruoslahti,et al.  Molecular Profiling of Heart Endothelial Cells , 2005, Circulation.

[18]  Yan Li,et al.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy , 2004, Nature.

[19]  E. Ruoslahti,et al.  Peptide Targeting of Tumor Lymph Vessels , 2008, Annals of the New York Academy of Sciences.

[20]  E. Ruoslahti.  Specialization of tumour vasculature , 2002, Nature Reviews Cancer.

[21]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[22]  S. Dowdy,et al.  TAT transduction: the molecular mechanism and therapeutic prospects. , 2007, Trends in molecular medicine.

[23]  D. Hanahan,et al.  Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. , 2003, Cancer cell.

[24]  Erkki Ruoslahti,et al.  Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.

[25]  R Pasqualini,et al.  Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. , 1998, The Journal of clinical investigation.

[26]  P. Lundin,et al.  Distinct uptake routes of cell-penetrating peptide conjugates. , 2008, Bioconjugate chemistry.

[27]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[28]  E. Ruoslahti,et al.  C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration , 2009, Proceedings of the National Academy of Sciences.

[29]  Erkki Ruoslahti,et al.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.

[30]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.